Prosjekter med finansiering etter utlysning av programmidler i 2016:
| Prosjekttittel | Søkerinstitusjon | Prosjektleder | Tildeling (kr) |
| Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple Sclerosis (RAM-MS) | Helse Bergen HF | Lars Bø | 19 970 000 |
| A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in combination with Dabrafenib/Trametinib or Pembrolizumab in metastatic melanoma: Identification of predictive markers of response | Helse Bergen HF | Oddbjørn Straume | 17 570 000 |
| Acetylsalisylic acid as secondary prevention in colorectal cancer (ASAC Trial) | Oslo universitetssykehus HF | Bjørn Atle Bjørnbeth | 13 840 000 |
| The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study | Oslo universitetssykehus HF | Håvard Ove Skjerven | 19 320 000 |
| A Norwegian multicentre trial assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring, the NOR-DRUM study | Diakonhjemmet Sykehus | Espen A. Haavardsholm | 12 430 000 |
| PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA-2): A randomized, placebo-controlled, multicenter Trial | Akershus universitetssykehus HF | Torbjørn Omland | 20 000 000 |
| Tenecteplase in wake-up ischaemic stroke trial – TWIST | Universitetssykehuset Nord-Norge HF | Ellisiv B. Mathiesen | 15 490 000 |
Prosjekter med finansiering etter utlysning av programmidler i 2017:
| Prosjekttittel | Søkerinstitusjon | Prosjektleder | Tildeling (kr) |
| BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function (BETAMI trial) | Oslo universitetssykehus HF | Dan Atar | 19 998 270 |
| Improved prediction of outcome by global strain and mechanical dispersion in patients with myocardial infarction, heart failure and primary prophylactic internal defibrillator. | Oslo universitetssykehus HF | Thor Edvardsen | 15 493 000 |
| Establishment of Molecular profiling for Individual clinical routine Treatment decisions in Early Breast Cancer (EMIT) – clinical trials | Oslo universitetssykehus HF | Bjørn Naume | 17 568 500 |
| BackToBasic | Oslo universitetssykehus HF | John-Anker Zwart | 13 840 000 |
| Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing – INSTAR | St. Olav’s Hospital HF | Henrik Døllner | 19 322 500 |
| Immunotherapy for Hematological Malignancies – A Path to Cure | St. Olav’s Hospital HF | Henrik Hjorth-Hansen | 12 431 000 |
| Sphenopalatine ganglion block in chronic migraine (MIBLOCK) | St. Olav’s Hospital HF | Anders Mattias Linde | 18 724 100 |
| Changing the speciaist mental health care | Helse Bergen HF | Gerd Kvale | 19 974 000 |